Bevacizumab and type 1 idiopathic macular telangiectasia

Abstract

Sir, Determination of seasonal allergic conjunctivitis variation using internet search engine data A common and potentially debilitating disease, seasonal allergic rhinoconjunctivitis (SAR) can greatly affect the quality of life and is associated with lost productivity.

Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab

“…Visual loss is mainly caused by cystoid macular oedema (CMO) and formation of hard exudates, which are the hallmark features of the disease [ 3 ]. Treatment with laser photocoagulation, photodynamic therapy [ 4 ], and intravitreal antivascular endothelial growth factor (anti-VEGF) agents (e.g., bevacizumab) [ 5 – 7 ] has shown mixed results. To the best of our knowledge, this is the first case study describing the use of intravitreal aflibercept for CMO in a case of type 1 IMT which was refractory to bevacizumab and had suboptimal response to macular laser.…”

Phakic Cystoid Macular Edema Secondary to Idiopathic Macular Telangiectasia Type 1 Responsive to Topical Anti-Inflammatory Agents

“…[4][5][6][7] We here broaden the range of therapeutic possibilities by reporting successful resolution of CME with topical steroidal and non-steroidal anti-inflammatory agents alone in a phakic patient with bilateral leaking macular telangiectasias consistent with an unusual bilateral presentation of IMT type 1. These topical agents may be an effective and less-invasive treatment option for CME secondary to IMT type 1.…”

Efficacy of Intravitreal Aflibercept in Macular Telangiectasia Type 1 Is Linked to the Ocular Angiogenic Profile

“…Intravitreal anti–vascular endothelial growth factor (VEGF) therapy has also been assessed, with inconstant results. Although bevacizumab 6 , 7 and ranibizumab 8 , 9 showed some efficacy in reducing macular edema and improving vision, three case series reported that only a minority of patients responded favorably to intravitreal bevacizumab. 10 – 12 Recently, three groups reported that MacTel 1 patients may be nonresponders or become refractory to bevacizumab 13 – 15 or ranibizumab, 15 including two case reports describing a favorable response after switching to intravitreal aflibercept.…”